ArticleObesity facts2020
Experiences with Glucagon-Like Peptide-1 Receptor Agonist in Children with Acquired Hypothalamic Obesity.
Article in Obesity facts, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Hypothalamic syndrome and acquired hypothalamic obesity: from fragmented care to integrated multidisciplinary management.Pituitary · 2026Review
- Semaglutide use for hypothalamic obesity and type 2 diabetes mellitus after suprasellar germinoma treatment.JCEM case reports · 2026Article
- Effectiveness and safety of GLP-1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real-world study.Diabetes, obesity & metabolism · 2026Article
- Hunger, satiety, and eating behavior after craniopharyngioma - narrative review on current management and future therapeutic perspectives.Frontiers in endocrinology · 2026Review
- Pharmacological Treatment for Adamantinomatous Craniopharyngioma.Current oncology reports · 2025Review
- Semaglutide treatment in hypothalamic obesity: Two-Year outcomes on body composition, appetite, and quality of life.Pituitary · 2025Article
- BMI trajectories in the first 3 months after childhood craniopharyngioma resection: a plea for early management of BMI changes.Endocrine connections · 2025Article
- Treatment of Hypothalamic Obesity With GLP-1 Analogs.Journal of the Endocrine Society · 2024Review
- Semaglutide as a promising treatment for hypothalamic obesity: a six-month case series on four females with craniopharyngioma.Pituitary · 2024Article
- Acquired hypothalamic obesity: A clinical overview and update.Diabetes, obesity & metabolism · 2024Article
- Hypothalamic syndrome.Nature reviews. Disease primers · 2022Review
- Treatment of Acquired Hypothalamic Obesity: Now and the Future.Frontiers in endocrinology · 2022Review
- Dextroamphetamine Treatment in Children With Hypothalamic Obesity.Frontiers in endocrinology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHypothalamic obesity (HO) in children after treatment for a tumor in the suprasellar region has severe implications. Previous studies have shown various effects of glucagon-like peptide-1 (GLP-1) receptor agonist in acquired HO, but in adults only. We present our experience of GLP-1 receptor agonist (exenatide) treatment during a 1-year period on body mass index (BMI) in children with acquired HO. PATIENTS AND
methodsChildren with severe weight gain after treatment for suprasellar tumor were given 2 mg exenatide weekly for a 12-month period. All had undergone previous dietary intervention. BMI standard deviation score (SDS), weight change, and adverse effects were assessed.
resultsFive children with a mean age of 15.4 years (range 13-18) and a mean follow-up time of 8.4 years (mean age of 7.0 years at the time of brain tumor diagnosis) were treated with GLP-1 receptor agonist. After 1 year, BMI SDS or absolute weight had not changed significantly compared to the period without treatment (BMI SDS change +0.005, 95% CI -0.07 to 0.08, p = 0.89, and absolute weight change +1.5 kg, 95% CI -0.08 to 3.1, p = 0.061). Only 1 patient experienced weight loss after 1 year (-5.4 kg, BMI SDS -0.33). All patients experienced mild side effects, such as injection pain or nausea, and 2 patients stopped treatment upon their own request after 8 and 11 months, respectively.
conclusionsIn this small cohort, we found little effect of GLP-1 receptor agonist in the treatment for acquired HO. Future research should focus on the prevention of HO or, if prevention is not possible, on alternative, individualized interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.